Brief: Reata Pharmaceuticals Says Qtrly Adjusted Loss Per Share $1.25

Reata Pharmaceuticals

01/03/2021 14:05

March 1 (Reuters) - Reata Pharmaceuticals Inc  RETA.O :
    * REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND
FULL
YEAR 2020 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL
DEVELOPMENT PROGRAMS
    * REATA PHARMACEUTICALS -  PLANNING TO AMEND FALCON PROTOCOL
TO
INCREASE TARGET ENROLLMENT TO 550 PATIENTS, EXPECT TO COMPLETE
ENROLLMENT BY 2021 END
    * REATA PHARMACEUTICALS INC - EXPECTS EXISTING CASH AND CASH
EQUIVALENTS WILL BE SUFFICIENT TO ENABLE IT TO FUND OPERATIONS
THROUGH MID-2024
    * REATA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $1.90
    * REATA PHARMACEUTICALS INC - QTRLY ADJUSTED LOSS PER SHARE
$1.25

Source text for Eikon:  ID:nGNX7w6Xvp 
Further company coverage:  RETA.O 

 ((Reuters.Briefs@thomsonreuters.com;))